Appointments

Stephen Hermitage joins Sai Life Sciences

Published

on

Contract Research, Development & Manufacturing Organisation (CRO-CDMO Sai Life Sciences has announced the appointment of Stephen Hermitage as Vice President, CMC.

Hermitage will join the global R&D leadership team at Sai Life Sciences, where he will add further deep scientific, process development and drug development experience to the R&D organisation.

Hermitage joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.

Sai Life Sciences CEO, Sauri Gudlavalleti, said:

“Over the past few years, our team has established a formidable reputation for itself as a high-quality scientific unit that can solve complex chemistry challenges.

“I am delighted to welcome Steve, a pharma industry veteran, onboard at Sai Life Sciences.

“His addition to our global delivery team further strengthens our ongoing efforts to build strong client partnerships and exceed client expectations by raising the bar on innovation, speed, and efficiency.”Throughout his more than 24 years at GSK, Hermitage worked with many project leaders and their teams to deliver the API and regulatory submissions that facilitate preclinical and clinical activities across the whole development lifecycle.

The new Vice President gained significant experience of working with CDMOs in India, China and Europe having led the technical externalisation group within Chemical Development.

Steve Hermitage said:

“I am incredibly excited to join Sai Life Sciences at a transformative time for the company.

“Throughout all my interactions with colleagues in the company it is clear that there is a collective ambition to build a world leading organisation that delivers Projects for customers by blending strong science with efficient manufacturing capability whilst maintaining high standards in Safety and Quality.”

Hermitage holds a BA & MA from Oxford University, a PhD from Liverpool University and conducted Postdoc studies at the University of Cambridge.

Click to comment

Trending stories

Exit mobile version